Current Gastroenterology Reports最新文献_第3页

Update in Inflammatory Bowel Disease Management in the Elderly. 老年炎症性肠病管理的最新进展。

Current Gastroenterology Reports Pub Date : 2025-08-04 DOI: 10.1007/s11894-025-01005-2

Farhad Peerani

{"title":"Update in Inflammatory Bowel Disease Management in the Elderly.","authors":"Farhad Peerani","doi":"10.1007/s11894-025-01005-2","DOIUrl":"https://doi.org/10.1007/s11894-025-01005-2","url":null,"abstract":"Purpose of review: This review article aims to summarize the safety and efficacy of medical therapies in elderly inflammatory bowel disease (IBD) patients contextualizing the therapies within the framework of polypharmacy, comorbidities and frailty.Recent findings: Anti-TNF therapies are the most extensively studied advanced therapy in elderly IBD patients. Based on most published studies, elderly IBD patients on anti-TNF therapy versus no advanced therapy demonstrate decreased treatment persistence that could be attributed to both diminished clinical response and increased adverse events. Caution should be used when considering Janus Kinase inhibitors in the elderly given the risk of infection and the possible increased risk of thrombosis. The majority of literature on the medical management of elderly IBD patients revolves around retrospective and observational studies. Further prospective research is required in the areas of disease pathophysiology, comparative effectiveness of therapies and frailty to better inform clinical practice. Multidisciplinary care models can best position elderly IBD patients to obtain optimal outcomes.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"56"},"PeriodicalIF":0.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Neoadjuvant Therapy in Remodeling Surgical Approaches for Gastrointestinal Malignancies. 新辅助治疗在胃肠道恶性肿瘤手术入路重塑中的作用。

Current Gastroenterology Reports Pub Date : 2025-07-30 DOI: 10.1007/s11894-025-01003-4

Daniella Ifeoluwatomiwa Odunsi, Hanna Mohammed Sherief, Shaikha Alhajeri, Kinitoli Rochill, Khadeeja Mahjoor, Gonzalo Navarro, Dalila Marra, Joud Abourdan, Jurgen Baldelomar Ortiz, Ahmad Mahmood Rolse, Manju Rai

{"title":"Role of Neoadjuvant Therapy in Remodeling Surgical Approaches for Gastrointestinal Malignancies.","authors":"Daniella Ifeoluwatomiwa Odunsi, Hanna Mohammed Sherief, Shaikha Alhajeri, Kinitoli Rochill, Khadeeja Mahjoor, Gonzalo Navarro, Dalila Marra, Joud Abourdan, Jurgen Baldelomar Ortiz, Ahmad Mahmood Rolse, Manju Rai","doi":"10.1007/s11894-025-01003-4","DOIUrl":"10.1007/s11894-025-01003-4","url":null,"abstract":"Purpose of review: This review explores the evolving role of neoadjuvant therapy (NAT) in the management of gastrointestinal (GI) malignancies, emphasizing its impact on surgical resectability, tumor downstaging, and survival outcomes. It examines how NAT is reshaping traditional surgical approaches across GI cancers.Recent findings: Recent evidence highlights the integration of chemotherapy, radiotherapy, immunotherapy, and targeted therapies in NAT protocols for esophageal, gastric, colorectal, pancreatic, and hepatobiliary cancers. Studies report improved R0 resection rates, reduced lymph node positivity, and enhanced eligibility for organ-preserving procedures. Precision medicine and artificial intelligence are emerging as tools to refine patient selection and predict therapeutic responses. NAT has transformed GI cancer care from a surgery-first model to a multimodal, biology-driven approach. While its benefits are substantial, challenges persist in toxicity management and treatment optimization. Future research should focus on refining protocols, enhancing predictive models, and advancing personalized therapeutic strategies to maximize patient outcomes.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"55"},"PeriodicalIF":0.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Barrett's Esophagus in the Context of Achalasia. 贲门失弛缓症患者Barrett食管的治疗。

Current Gastroenterology Reports Pub Date : 2025-07-28 DOI: 10.1007/s11894-025-00996-2

Margaret J Zhou, John O Clarke

引用次数: 0

Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use? 雷司替米治疗脂肪肝：数据支持广泛使用吗？

Current Gastroenterology Reports Pub Date : 2025-07-22 DOI: 10.1007/s11894-025-01002-5

Winston Dunn, Naim Alkhouri

引用次数: 0

Practical Tips for Diagnosis and Management of Concomitant Inflammatory Spondyloarthritis and Inflammatory Bowel Disease. 诊断和治疗伴有炎症性脊柱炎和炎症性肠病的实用技巧。

Current Gastroenterology Reports Pub Date : 2025-07-14 DOI: 10.1007/s11894-025-00990-8

Katherine Falloon, Michael Forney, Shashank Cheemalavagu, M Elaine Husni, Florian Rieder

引用次数: 0

Anti-Reflux Mucosectomy: Our Experience & Thoughts For The Future. 抗反流性粘膜切除术：我们的经验和对未来的思考。

Current Gastroenterology Reports Pub Date : 2025-07-11 DOI: 10.1007/s11894-025-00992-6

Jean-Christophe N Rwigema, Michael B Ujiki

引用次数: 0

Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives. 粪便微生物群移植治疗肠-脑相互作用疾病：当前的见解，有效性和未来的前景。

Current Gastroenterology Reports Pub Date : 2025-07-09 DOI: 10.1007/s11894-025-01001-6

Taha Bin Arif, John A Damianos, Asad-Ur- Rahman, Nimra Hasnain

{"title":"Fecal Microbiota Transplantation for Disorders of Gut-Brain Interaction: Current Insights, Effectiveness, and Future Perspectives.","authors":"Taha Bin Arif, John A Damianos, Asad-Ur- Rahman, Nimra Hasnain","doi":"10.1007/s11894-025-01001-6","DOIUrl":"https://doi.org/10.1007/s11894-025-01001-6","url":null,"abstract":"Purpose of review: Dysbiosis can disrupt intestinal barrier integrity and impact the immune and nervous systems, playing a significant role in developing disorders of gut-brain interaction (DGBI). This review aims to provide a comprehensive understanding of dysbiosis and its role in DGBI while examining the latest advancements in fecal microbiota transplantation (FMT). It also highlights key challenges in the field and outlines critical directions for future research to optimize FMT strategies, ultimately improving patient outcomes in this evolving treatment area.Recent findings: In DGBI, dysbiosis triggers immune responses, increases gut permeability, and disrupts nervous system signaling, with contributing factors including diet, antibiotics, stress, and infections. Individuals with DGBI exhibit distinct microbial imbalances, such as an increased Firmicutes-to-Bacteroidetes ratio and reduced beneficial bacteria. FMT has shown mixed results, with factors like patient selection, treatment protocols, and microbiome diversity influencing outcomes. While FMT can improve symptoms in refractory irritable bowel syndrome (IBS), effects may fade over time, requiring repeat treatments. Future FMT approaches should focus on targeted microbial interventions, considering the role of archaea, fungi, and microbial metabolites, while prioritizing optimal donor selection and large-scale trials for long-term efficacy. Despite the promising findings, FMT has not yet been widely endorsed in clinical guidelines due to the variability and heterogeneity of the data available. While much of the research has focused on IBS, studies have also explored the impact of FMT on other conditions such as functional diarrhea, functional constipation, and functional dyspepsia, which all exhibit altered microbial profiles.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"50"},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal Motility Effects of GLP-1 Receptor Agonists. GLP-1受体激动剂对胃肠运动的影响。

Current Gastroenterology Reports Pub Date : 2025-07-07 DOI: 10.1007/s11894-025-00995-3

Danielle Bellavance, Samantha Chua, Hiroshi Mashimo

{"title":"Gastrointestinal Motility Effects of GLP-1 Receptor Agonists.","authors":"Danielle Bellavance, Samantha Chua, Hiroshi Mashimo","doi":"10.1007/s11894-025-00995-3","DOIUrl":"https://doi.org/10.1007/s11894-025-00995-3","url":null,"abstract":"Purpose of review: This review summarizes the current understanding of the physiologic influence of GLP-1 RAs on gastrointestinal motility, highlights key clinical implications of these effects, and defines areas for future investigation.Recent findings: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of diabetes and obesity and are increasingly being identified as promising therapies for a wide range of conditions. GLP-1 RAs mimic naturally occurring GLP-1, an enterohormone produced in response to oral intake that regulates glucose metabolism and promotes weight loss. While GLP-1 RAs target a wide range of organ systems, their impacts on gastrointestinal motility are widely regarded as a major mechanism by which they exert their metabolic effects. However, the drugs' alterations in gut motility may account for many of their commonly reported adverse effects including nausea, vomiting, early satiety, dyspepsia, and bowel habit changes. GLP-1 RAs alter gastrointestinal motility at all levels of the GI tract, with delayed gastric emptying being the most well characterized. The effects of GLP-1 RAs on gastrointestinal motility have important clinical implications, including possible increased periprocedural aspiration risk and potential challenges with medication adherence and tolerability.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"49"},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postpartum Anorectal and Pelvic Floor Disorders: Evaluation, Treatment, and Prevention. 产后肛门直肠和盆底疾病：评估、治疗和预防。

Current Gastroenterology Reports Pub Date : 2025-07-03 DOI: 10.1007/s11894-025-01000-7

Lalitha Sitaraman, Christina Lewicky-Gaupp, Satish Sc Rao

{"title":"Postpartum Anorectal and Pelvic Floor Disorders: Evaluation, Treatment, and Prevention.","authors":"Lalitha Sitaraman, Christina Lewicky-Gaupp, Satish Sc Rao","doi":"10.1007/s11894-025-01000-7","DOIUrl":"10.1007/s11894-025-01000-7","url":null,"abstract":"Purpose of review: Postpartum anorectal and pelvic floor disorders (PFD) are common, though under-recognized. There is limited knowledge regarding their diagnosis, treatment, and prevention. Here we provide a critical review of this topic and highlight knowledge gaps and treatment options for these problems.Recent findings: Recent advances include dynamic 3D and 4D ultrasound of the pelvic floor to reveal pathology, anal sphincter defects, and pelvic organ prolapse. Treatments for fecal incontinence include anal inserts, vaginal inserts, translumbosacral neuromodulation therapy (not yet studied postpartum), and increasing data for safety of sacral nerve stimulators in pregnancy. Exercise, pelvic floor muscle training, and use of special devices show mixed results. Postpartum anorectal and pelvic floor disorders include fecal and/or flatus incontinence, constipation, hemorrhoids, pelvic organ prolapse, and urinary incontinence. Many patients present years later, and most suffer in silence. Early recognition, appropriate treatment, and preventative measures could mitigate these problems.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"27 1","pages":"48"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underwater Endoscopy: Diving into the Future of Gastrointestinal Endoscopy. 水下内窥镜：潜入胃肠道内窥镜的未来。

Current Gastroenterology Reports Pub Date : 2025-06-30 DOI: 10.1007/s11894-025-00993-5

Garvit Chhabra, Amal Shine, Nanlong Liu

引用次数: 0